-
Subject Areas on Research
-
2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator.
-
A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
-
A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
-
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
-
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
-
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
-
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
-
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
-
A comparison of antiangiogenic therapies for the prevention of liver metastases.
-
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
-
A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.
-
A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
-
A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
-
A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
-
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
-
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
-
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
-
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
-
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
-
A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.
-
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
-
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.
-
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
-
Abnormal angiogenesis in diabetes mellitus.
-
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
-
Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
-
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
-
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
-
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
-
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
-
Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place?
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
-
Aflibercept-related sterile inflammation.
-
Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
-
Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema.
-
All-trans-retinal sensitizes human RPE cells to alternative complement pathway-induced cell death.
-
An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
-
An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone.
-
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
-
Angiogenesis pathway inhibitors.
-
Angiogenesis.
-
Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Animal models of bleeding and tissue repair.
-
Anti-VEGF therapies in the clinic.
-
Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
-
Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy.
-
Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion.
-
Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
-
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
-
Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct.
-
Anti-angiogenic therapy for high-grade glioma.
-
Anti-angiogenic therapy in renal cell cancer.
-
Anti-vascular endothelial growth factor treatment for eye diseases.
-
Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor.
-
Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
-
Antiangiogenic therapies in epithelial ovarian cancer.
-
Antiangiogenic therapy for high-grade glioma.
-
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
-
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
-
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
-
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
-
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.
-
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
-
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
-
Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
-
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
-
Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).
-
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
-
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
-
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
-
Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma.
-
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
-
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
-
Author reply: To PMID 24393349.
-
Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.
-
Avastin: more questions than answers. .
-
Bacillary Detachment in Neovascular Age-Related Macular Degeneration: Incidence, Clinical Features, and Response to Anti-VEGF Therapy.
-
Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.
-
Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
-
Best practices for treatment of retinal vein occlusion.
-
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
-
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
-
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
-
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
-
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
-
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
-
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
-
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
-
Bevacizumab for retinopathy of prematurity.
-
Bevacizumab for the treatment of high-grade glioma.
-
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
-
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
-
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
-
Bevacizumab therapy for glioblastoma: a passionate discussion.
-
Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
-
Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
-
Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.
-
Biomarkers of response and resistance to antiangiogenic therapy.
-
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
-
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
-
CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
-
CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes.
-
COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
-
CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
-
Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
-
Caspase 3 in dying tumor cells mediates post-irradiation angiogenesis.
-
Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration.
-
Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials.
-
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
-
Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
-
Choroidal neovascularization in a child with infantile primary hyperoxaluria treated with bevacizumab.
-
Choroidal neovascularization in pathological myopia.
-
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.
-
Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.
-
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
-
Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.
-
Colon cancer, version 3.2014.
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
-
Combination therapy for macular edema secondary to retinal vein occlusion.
-
Combinations of Bevacizumab With Cancer Immunotherapy.
-
Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
-
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
-
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
-
Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience.
-
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
-
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
-
Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years.
-
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
-
Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence.
-
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.
-
Corneal penetration of topical and subconjunctival bevacizumab.
-
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
-
Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
-
Correspondence.
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
-
Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy.
-
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
-
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
-
Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.
-
Current and Emerging Treatment for Diabetic Macular Edema.
-
Current insights on the biology and clinical aspects of VEGF regulation.
-
Current management of diabetic tractional retinal detachments.
-
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling.
-
DYNAMIC CHANGES OF THE ANTERIOR CHAMBER ANGLE PRODUCED BY INTRAVITREAL ANTI-VASCULAR GROWTH FACTOR INJECTIONS.
-
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
-
Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
-
Diabetic macular edema: Evidence-based management.
-
Dietary glycine inhibits angiogenesis during wound healing and tumor growth.
-
Differences in Presentation and Outcomes in Males and Females With Branch Retinal Vein Occlusion.
-
Different patterns of angiogenesis in sarcomas and carcinomas.
-
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
-
Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
-
Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion.
-
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
-
Diffusion of technologies for the care of older adults with exudative age-related macular degeneration.
-
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
-
Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections.
-
Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT.
-
Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
-
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
-
Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.
-
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
-
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
-
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
-
Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism.
-
Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma.
-
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.
-
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials.
-
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
-
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
-
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
-
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
-
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
-
Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly.
-
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
-
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
-
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
-
Effect of pazopanib on tumor microenvironment and liposome delivery.
-
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
-
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
-
Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
-
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
-
Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
-
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
-
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
-
Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.
-
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
-
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
-
Endoglin Targeting: Lessons Learned and Questions That Remain.
-
Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
-
Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis.
-
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
-
Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study.
-
Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.
-
Eyes With Acute, Treatment-Naïve CRVO and Foveal Intraretinal Hemorrhage: Characteristics and Outcomes.
-
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
-
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
-
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
-
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
-
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
-
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
-
HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
-
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer.
-
Hypoxia, angiogenesis, and lung cancer.
-
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
-
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.
-
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
-
Immediate and long-term consequences of vascular toxicity during zebrafish development.
-
Immunological Aspects of Age-Related Macular Degeneration.
-
Immunological disruption of antiangiogenic signals by recruited allospecific T cells leads to corneal allograft rejection.
-
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
-
Impact and Implication of Fovea-Involving Intraretinal Hemorrhage after Acute Branch Retinal Vein Occlusion.
-
Impact of Baseline Quantitative OCT Features on Response to Risuteganib for the Treatment of Dry Age-Related Macular Degeneration: The Importance of Outer Retinal Integrity.
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
-
Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.
-
Improvement of Recalcitrant Diabetic Macular Edema After Peritoneal Dialysis.
-
Improving Outcomes for Patients With Diabetic Macular Edema.
-
In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide.
-
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
-
Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy.
-
Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections.
-
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.
-
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
-
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
-
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
-
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
-
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
-
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
-
Interception of host angiogenic signalling limits mycobacterial growth.
-
Interventions for branch retinal vein occlusion: an evidence-based systematic review.
-
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
-
Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
-
Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
-
Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.
-
Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
-
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
-
Intravitreal aflibercept for diabetic macular edema.
-
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
-
Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
-
Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
-
Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.
-
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
-
Is This a 737 Max Moment for Brolucizumab?
-
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
-
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
-
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
-
Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
-
Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
-
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
-
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
-
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.
-
Making genuine progress against metastatic breast cancer.
-
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
-
Management of diabetic retinopathy: a systematic review.
-
Management of hearing in pediatric NF2.
-
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
-
Medicare costs for neovascular age-related macular degeneration, 1994-2007.
-
Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
-
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.
-
Molecular markers for incidence, prognosis, and response to therapy.
-
Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
-
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
-
Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.
-
Myopic choroidal neovascularisation: current concepts and update on clinical management.
-
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.
-
Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
-
Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment.
-
New drug development in metastatic prostate cancer.
-
New drugs in prostate cancer.
-
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
-
Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.
-
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
-
Novel antiangiogenic therapies for renal cell cancer.
-
Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
-
Novel therapeutic approaches to advanced prostate cancer.
-
Novel therapies for pancreatic adenocarcinoma.
-
Novel therapies for pancreatic adenocarcinoma.
-
OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study.
-
Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications.
-
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
-
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.
-
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
-
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
-
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
-
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
-
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.
-
PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
-
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?
-
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
-
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
-
Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.
-
Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.
-
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
-
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
-
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
-
Phase I study of pazopanib plus TH-302 in advanced solid tumors.
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors.
-
Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.
-
Phase I trial of pazopanib in patients with advanced cancer.
-
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
-
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
-
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
-
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.
-
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
-
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
-
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
-
Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
-
Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
-
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
-
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
-
Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management.
-
Polypoidal choroidal vasculopathy and systemic lupus erythematosus.
-
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
-
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
-
Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab.
-
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
-
Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
-
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
-
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.
-
Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
-
Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay.
-
RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
-
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.
-
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
-
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
-
Ranibizumab for neovascular age-related macular degeneration.
-
Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
-
Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE.
-
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
-
Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography.
-
Rare Complication of Sclerochoroidal Calcifications.
-
Rate of intraoperative complications during cataract surgery following intravitreal injections.
-
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
-
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
-
Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
-
Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy.
-
Recurrent Tube Erosions with Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration.
-
Recurrent malignant gliomas.
-
Region-specific ischemia, neovascularization and macular oedema in treatment-naïve proliferative diabetic retinopathy.
-
Reply.
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
-
Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.
-
Resveratrol prevention of oxidative stress damage to lens epithelial cell cultures is mediated by forkhead box O activity.
-
Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period.
-
Retinal vein occlusion: beyond the acute event.
-
Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD.
-
Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
-
Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
-
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
-
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
-
SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION.
-
SU5416 delays wound healing through inhibition of TGF-beta 1 activation.
-
Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
-
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
-
Safety of bevacizumab in patients with metastatic breast cancer.
-
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
-
Screening for angiogenic inhibitors in zebrafish to evaluate a predictive model for developmental vascular toxicity.
-
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
-
Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab.
-
Sex Differences in Presentation, Treatment Patterns, and Clinical Outcomes in Central Retinal Vein Occlusion.
-
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
-
Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy.
-
Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity.
-
Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
-
Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
-
Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
-
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
-
Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
-
Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
-
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
-
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.
-
Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis.
-
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
-
Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
-
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
-
Surrogate markers in antiangiogenesis clinical trials.
-
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
-
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
-
Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.
-
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
-
Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.
-
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
-
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
-
The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology.
-
The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
-
The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
-
The Role of Angiogenesis in Hepatocellular Carcinoma.
-
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
-
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
-
The development and testing of aptamers for cancer.
-
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
-
The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.
-
The emerging role of anti-angiogenic therapy for malignant glioma.
-
The mechanism of action of angiostatin: can you teach an old dog new tricks?
-
The natural history of retinal vein occlusion: what do we really know?
-
The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.
-
The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
-
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
-
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
-
The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.
-
Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology.
-
Therapy for non-clear cell histologies in renal cancer.
-
Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity.
-
Thrombospondin-based antiangiogenic therapy.
-
Topical bevacizumab therapy for corneal neovascularization.
-
Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
-
Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
-
Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis.
-
Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
-
Treatment of age-related macular degeneration.
-
Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
-
Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
-
Trends in Anti-Vascular Endothelial Growth Factor Agents and Panretinal Photocoagulation Use in Diabetic Retinopathy.
-
Trends in age-related macular degeneration management in Singapore.
-
Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration.
-
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
-
Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals.
-
Use of bevacizumab in recurrent glioblastoma.
-
VEGF inhibition and renal thrombotic microangiopathy.
-
VEGF inhibition and renal thrombotic microangiopathy.
-
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
-
Vascular endothelial growth factor and diabetic complications.
-
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
-
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
-
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
-
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
-
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
-
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
-
Keywords of People
-
Craciunescu, Oana,
Professor of Radiation Oncology,
Radiation Oncology
-
Curtis, Lesley H.,
Professor in Population Health Sciences,
Medicine, General Internal Medicine
-
Fekrat, Sharon,
Professor of Ophthalmology,
Ophthalmology, Vitreoretinal Diseases & Surgery
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Mruthyunjaya, Prithvi,
Adjunct Associate Professor in the Department of Ophthalmology,
Ophthalmology, Vitreoretinal Diseases & Surgery
-
Palmer, Gregory M.,
Associate Professor of Radiation Oncology,
Radiation Oncology
-
Pang, Herbert,
Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Toth, Cynthia Ann,
Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology,
Biomedical Engineering
-
Uronis, Hope Elizabeth,
Associate Professor of Medicine,
Medicine, Medical Oncology
-
Zafar, Syed Yousuf,
Adjunct Professor in the Department of Medicine,
Duke Science & Society